Dyslipidemia
Conditions
Interventions
Test group:Rosuvastatin + Jiang Zhi Qing Shen Capsules
Control group:Rosuvastatin + placebo
Sponsors
Zhengzhou Chinese Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Meeting the diagnostic criteria of primary dyslipidemia in Western medicine; (2) Meet the diagnostic criteria of the Chinese medical evidence (phlegm and turbidity blocking type); (3) Between the ages of 18 and 70 years old, with independent ability, regardless of gender; (4) have taken lipid-lowering drugs, but have stopped taking them for 15 days or more, and the lipid level has not reached the standard, but still meets the current diagnostic criteria (4) have taken lipid-lowering drugs, but have stopped taking them for 15 days or more, and the blood lipid level has not reached the standard, but still meets the current diagnosis criteria (5) Voluntary participation in the clinical trial, and signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) Secondary dyslipidemia: dyslipidemia disorders caused by long-term or high-dose medication, or dyslipidemia caused by endocrine diseases, liver and kidney diseases, etc. (1) Secondary dyslipidemia: dyslipidemia caused by long-term, high-dose medication, or dyslipidemia caused by endocrine diseases, liver and kidney diseases, etc; (2) Pregnant or lactating women, or women who are preparing for pregnancy; (3) Patients who are allergic to HMG-CoA reductase inhibitors; (4) Diseases related to weight change such as diabetes, peptic ulcer or malabsorption syndrome; (5) Familial dyslipidemia with a genetic predisposition due to genetic abnormalities; (6) Patients with mental illness; (7) Patients with severe liver disease or renal insufficiency, severe cardiac insufficiency and other major cardiovascular events; (8) Other patients who, in the opinion of the investigator, are not suitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total cholesterol;Triglycerides;Low-density lipoprotein cholesterol;High-density lipoprotein cholesterol; | — |
Secondary
| Measure | Time frame |
|---|---|
| Apolipoprotein A1;Apolipoprotein B;Lipoprotein (a);Fasting blood glucose; | — |
Countries
China
Contacts
Public ContactLi Dongyu
Zhengzhou Chinese Hospital
Outcome results
None listed